Longevity researchers stories

Apr 4, 2026

Small Molecule Drug Candidate Shows Promise for Rare Kidney Stone Disease with No Current Treatment

Scientists at the Buck Institute for Research on Aging demonstrated that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones in preclinical studies.

Apr 4, 2026·1 source

Apr 3, 2026

White House Proposes $5 Billion Cut to NIH Budget, Reducing Institutes from 27 to 22

Trump administration's 2027 budget proposal calls for cutting $5 billion from the National Institutes of Health and consolidating the number of institutes and centers from 27 to 22, though Congress is unlikely to approve the cuts.

Apr 3, 2026·2 sources

Top claims

▪An orally administered treatment for primary hyperoxaluria type 2 would offer a non-invasive option for managing the disease.
▪N-propargylglycine (N-PPG) protects against kidney failure in a mouse model of primary hyperoxaluria type 2.
▪An estimated 1,700 people in the United States suffer from primary hyperoxaluria type 2 (PH2).

Subtopics

Longevity & aging Longevity biotech founders Biomarkers & bloodwork testing Health Addiction & recovery AI policy

Aging biology experts

Related timelines

Longevity researchers stories

Small Molecule Drug Candidate Shows Promise for Rare Kidney Stone Disease with No Current Treatment

White House Proposes $5 Billion Cut to NIH Budget, Reducing Institutes from 27 to 22

Related timelines

US Congress

Venture capital funding

Iran War

Strait of Hormuz blockage

Trump administration